…
TALi Digital Limited, a digital health company, delivers diagnostic and therapeutic solutions to enhance attention cognitive function in Australia, New Zealand, and internationally. It offers ReadyAttentionGo!, a medical device that is a digital therapeutic cognitive training program designed to improve attention skills in children aged 3 to 10 years old; TALi Research and Development!; and You Can Do It! Education, an online social-emotional learning and mental health program for children and adolescents. The company was formerly known as Novita Healthcare Limited and changed its name to TALI Digital Limited in December 2019. TALi Digital Limited was incorporated in 2004 and is based in Hawthorn East, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Tali Digital Ltd (TD1.AU) is limited; available disclosures do not provide comprehensive detail about its core operations or market positioning. If the company advances a viable digital services or technology offering and secures stable funding, it may benefit from ongoing digital adoption trends and scalable revenue potential, which could support long-term growth.
Material risks include scarce public disclosure, low trading liquidity, execution and financing uncertainty common to early-stage listed companies, and the possibility of sustained losses or dilutive capital raisings.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -2.43M | -0.66M | -3.18M | -2.26M | -5.83M |
| Net income | -2.21M | -0.66M | -3.12M | -2.26M | -5.83M |
| Selling general administrative | 0.63M | 0.27M | 0.48M | 1.40M | 3.18M |
| Selling and marketing expenses | - | - | 0.00M | 0.19M | 1.01M |
| Gross profit | -0.47M | 0.00M | -0.45M | -1.49M | -3.59M |
| Reconciled depreciation | 0.16M | - | 0.18M | 0.32M | 0.37M |
| Ebit | -0.99M | - | -1.23M | -2.27M | -5.76M |
| Ebitda | -0.83M | -0.71M | -1.05M | -1.95M | -5.39M |
| Depreciation and amortization | 0.16M | - | 0.18M | 0.32M | 0.37M |
| Operating income | -0.99M | -0.71M | -1.23M | -2.27M | -6.85M |
| Other operating expenses | 1.26M | 0.71M | 1.23M | -0.02M | -0.59M |
| Interest expense | - | - | - | -0.01M | 0.07M |
| Tax provision | -0.21M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.01M | 0.05M | 0.08M | 0.01M | 0.08M |
| Net interest income | 0.01M | 0.05M | 0.08M | 0.01M | -0.07M |
| Extraordinary items | - | - | - | - | 0.00M |
| Income tax expense | -0.21M | - | -0.07M | 0.75M | 0.93M |
| Total revenue | 0.27M | 0.00M | 0.00M | 0.03M | 0.01M |
| Total operating expenses | 0.52M | 0.71M | 1.20M | 3.05M | 6.63M |
| Cost of revenue | 0.75M | - | 0.45M | 1.52M | 3.61M |
| Total other income expense net | -1.44M | 0.05M | -1.96M | 0.76M | 0.86M |
| Net income from continuing ops | -2.21M | -0.66M | -3.12M | -2.26M | -5.83M |
| Net income applicable to common shares | - | -0.66M | -3.12M | -2.26M | -5.83M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 1.08M | 2.66M | 2.19M | 8.09M | 7.54M |
| Intangible assets | - | - | - | 4.36M | 3.85M |
| Other current assets | 0.02M | - | 0.00M | - | 0.38M |
| Total liab | 0.44M | 0.39M | 0.04M | 2.92M | 3.01M |
| Total stockholder equity | 0.65M | 2.27M | 2.15M | 5.17M | 4.54M |
| Other current liab | 0.19M | - | 0.03M | 0.23M | 0.08M |
| Common stock | 216.08M | - | 214.84M | 214.84M | 211.04M |
| Capital stock | 216.08M | 215.58M | - | 214.84M | 211.04M |
| Retained earnings | -215.78M | -213.88M | -213.22M | -210.13M | -207.19M |
| Other liab | - | - | - | 1.96M | 1.80M |
| Good will | - | 1.31M | - | - | - |
| Other assets | - | - | - | - | 0.83M |
| Cash | 0.97M | 1.29M | 2.12M | 2.99M | 1.85M |
| Cash and equivalents | - | - | - | - | 1.85M |
| Total current liabilities | 0.44M | 0.27M | 0.04M | 0.96M | 0.75M |
| Current deferred revenue | 0.19M | - | - | 0.17M | 0.15M |
| Net debt | -0.97M | - | -2.12M | -2.48M | -1.34M |
| Short term debt | - | - | - | 0.51M | 0.04M |
| Short long term debt | - | - | - | 0.51M | 0.04M |
| Short long term debt total | - | - | - | 0.51M | 0.50M |
| Other stockholder equity | - | - | - | -4.70M | -2.74M |
| Property plant equipment | - | - | - | 0.01M | 0.03M |
| Total current assets | 1.08M | 1.35M | 2.19M | 3.72M | 2.84M |
| Net tangible assets | - | - | - | 0.81M | 0.69M |
| Short term investments | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net receivables | 0.04M | 0.03M | 0.06M | 0.71M | 0.61M |
| Long term debt | - | - | - | 0.00M | 0.46M |
| Inventory | 0.04M | 0.03M | - | - | -0.28M |
| Accounts payable | 0.06M | 0.12M | 0.01M | 0.05M | 0.48M |
| Accumulated other comprehensive income | 0.34M | - | 0.53M | 0.47M | 0.69M |
| Non currrent assets other | - | - | - | -4.37M | 0.83M |
| Non current assets total | 0.00M | 1.31M | - | 4.37M | 4.70M |
| Capital lease obligations | - | - | - | - | 0.04M |
| Long term debt total | - | - | - | 0.00M | 0.46M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | -0.08M | -1.10M | - | -0.82M | -0.01M |
| Change to liabilities | - | - | - | -0.12M | 0.02M |
| Total cashflows from investing activities | -0.08M | -1.10M | 0.00M | -0.82M | -0.01M |
| Net borrowings | - | - | -0.50M | - | 0.47M |
| Total cash from financing activities | 0.50M | 0.75M | -0.50M | 3.96M | 3.46M |
| Change to operating activities | - | - | - | 0.12M | 0.70M |
| Net income | -2.21M | -0.66M | -3.12M | -2.26M | -6.94M |
| Change in cash | -0.32M | -0.83M | -0.86M | 1.14M | -0.88M |
| Begin period cash flow | 1.29M | 2.12M | 2.99M | 1.85M | 2.73M |
| End period cash flow | 0.97M | 1.29M | 2.12M | 2.99M | 1.85M |
| Total cash from operating activities | -0.74M | -0.47M | -0.36M | -2.00M | -4.33M |
| Issuance of capital stock | 0.58M | 0.80M | - | 4.21M | 3.27M |
| Depreciation | 0.16M | - | 0.18M | 0.06M | 0.13M |
| Other cashflows from investing activities | - | -1.10M | - | - | 0.00M |
| Change to inventory | 0.01M | -0.03M | - | - | - |
| Change to account receivables | -0.02M | 0.04M | 0.65M | -0.10M | 0.23M |
| Sale purchase of stock | -0.08M | -0.05M | 0.00M | -0.26M | -0.28M |
| Other cashflows from financing activities | - | -0.05M | -0.50M | -0.82M | 0.47M |
| Change to netincome | - | - | - | 0.04M | 0.17M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.82M | 0.01M |
| Change in working capital | 0.11M | 0.15M | 0.33M | -0.10M | 0.23M |
| Stock based compensation | - | - | 0.10M | 0.04M | 0.17M |
| Other non cash items | 1.43M | -0.63M | 2.14M | 0.20M | 2.48M |
| Free cash flow | -0.74M | -0.47M | -0.36M | -2.82M | -4.34M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TD1 Tali Digital Ltd |
-0.00 2.94% |
0.07 | - | 7.46 | 31.86 | 14.20 | 35.11 | -1.56 |
| PME Pro Medicus Ltd |
-4.52 2.18% |
202.79 | 81.98 | 106.38 | 83.13 | 43.70 | 74.38 | 95.34 |
| 4DX 4DMEDICAL Ltd |
-0.06 2.53% |
2.31 | - | - | 205.57 | 8.53 | 170.03 | -7.29 |
| CGS Cogstate Ltd |
0.12 3.30% |
3.76 | 33.80 | 27.86 | 9.59 | 6.95 | 6.35 | 19.27 |
| AYA ARTRYA Ltd |
-0.14 3.91% |
3.44 | - | - | 20505.14 | 7.00 | 16927.51 | 0.33 |
TALi Digital Limited, a digital health company, delivers diagnostic and therapeutic solutions to enhance attention cognitive function in Australia, New Zealand, and internationally. It offers ReadyAttentionGo!, a medical device that is a digital therapeutic cognitive training program designed to improve attention skills in children aged 3 to 10 years old; TALi Research and Development!; and You Can Do It! Education, an online social-emotional learning and mental health program for children and adolescents. The company was formerly known as Novita Healthcare Limited and changed its name to TALI Digital Limited in December 2019. TALi Digital Limited was incorporated in 2004 and is based in Hawthorn East, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Mary Elizabeth Brinson | CEO & Chief Medical Officer | NA |
| Ms. Magda Klapakis BSocSc, CPA, PostGradAcc | Head of Fin. & Financial Controller | NA |
| Mr. Pete Saunders | Chief Operations Officer | NA |
| Paul McKeon | Investor Relations Mang. | NA |
| Mr. David Turnbull | National Sales Mang. | NA |
| Mr. Lee Simpson | Marketing Mang. | NA |
| Mr. Tim Luscombe | Company Sec. | NA |
| Mr. M. Rose | Exec. Officer | NA |
| Ms. Magda Klapakis BSocSc, CPA, PostGradAcc | Head of Finance & Financial Controller | NA |
| Paul McKeon | Investor Relations Manager | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.